SAN ANTONIO (March 9, 2010) — Physicians, nurses and pharmacists are faced with a dizzying array of new drugs to consider when treating their cancer patients. A San Antonio conference March 19-20 about newly approved anticancer agents is intended to help clinicians address a variety of practical issues, such as treating early- and late-stage disease, using treatments in combination and managing side effects.
The meeting, “Practical Applications of New Agents in Oncology™,” will bring together scientists from renowned medical centers around the country including Memorial Sloan-Kettering in New York and the Cleveland Clinic in Ohio with faculty from the Cancer Therapy & Research Center at the UT Health Science Center San Antonio. Sponsor of the 12th annual meeting is the CTRC’s Institute for Drug Development, which has developed or tested at least 20 cancer drugs approved by the U.S. Food and Drug Administration (FDA) in recent years.
“We believe cancer patients have better outcomes and better quality of life when their health care professionals have the chance to receive updated information from outstanding opinion leaders about drugs that have been recently approved or are about to be approved,” observes Monica Mita, M.D., course co-director and assistant professor of hematology and medical oncology at the CTRC at the UT Health Science Center.
“Speakers will emphasize the drugs’ mechanism of action, efficacy, side effects and treatment of side effects,” Dr. Mita adds. “They also will talk about novel and promising drugs or pathways that could further change the way we practice. The face of modern oncology and hematology has changed tremendously in the last five to 10 years due to the development and approval of new drugs.”
Speakers will discuss several new agents to treat specific types of cancers or tumors: blood, breast, lung, gastrointestinal tract, kidney and soft tissue/muscle. Participants are invited to meet the experts over lunch.
Presenters include:
• Ronald Bukowski, M.D., Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio;
• Wendy Crabbe, R.N., UT Health Science Center San Antonio;
• Brad Frei, Pharm.D., University of the Incarnate Word;
• Robert Maki, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center, New York, N.Y.;
• Alain Mita, M.D., UT Health Science Center San Antonio;
• Monica Mita, M.D., UT Health Science Center San Antonio;
• Swaminathan Padmanabhan, M.D., UT Health Science Center San Antonio;
• Ramesh Ramanathan, M.D., TGen Clinical Research Services, Scottsdale, Ariz.;
• Peter Ravdin, M.D., Ph.D., UT Health Science Center San Antonio;
• Alan Sandler, M.D., Oregon Health & Science University, Portland, Ore.;
• Scott Soefje, Pharm.D., BCOP, UT Health Science Center San Antonio;
• Glen Weiss, M.D., The Translational Genomic Research Institute, Phoenix, Ariz.;
• Michelle Wright, R.N., UT Health Science Center San Antonio; and
• Stacey Young-McCaughan, R.N., Ph.D., UT Health Science Center San Antonio.
The meeting agenda follows. For more information or to register for the conference, which is to be held at the Omni San Antonio Hotel at the Colonnade, please visit www.newagents.org, or contact Marissa Howard, (210) 567-4435, howardm.uthscsa.edu.
Preliminary Program
Friday, March 19, 2010
6:00 pm – 8:00 pm Nursing/Pharmacy Session
6:00 pm– 6:30 pm Safe Handling of Chemo Agents
Wendy Crabbe, RN, UT Health Science Center, San Antonio, TX
Scott Soefje, PharmD, BCOP, UT Health Science Center, San Antonio, TX
6:30 pm – 6:45 pm Questions
6:45 pm – 7:15 pm Challenges of Oral Meds
Bradi Frei, PharmD, University of Incarnate Word, San Antonio, TX
Michelle Wright, RN, UT Health Science Center, San Antonio, TX
7:15 pm – 7:30 pm Questions
7:30 pm – 7:50 pm Update on FDA / GCP Regulations regarding Clinical Trials
Stacy Young McCaughan, RN, PhD, AOCN, UT Health Science Center, San Antonio, TX
7:50 pm – 8:00 pm Questions
Saturday, March 20, 2010
8:00 am – 5:30 pm
7:00 am – 8:00 am Registration and Continental Breakfast
8:00 am – 8:10 am Introduction
Monica Mita, MD, MSC, UT Health Science Center, San Antonio, TX
8:10 am – 8:40 am What are the new agents and how do they work? What is new on the horizon?
Alain C. Mita, MD, MSC, UT Health Science Center, San Antonio, TX
8:40 am – 8:50 am Questions/Answers
8:50 am – 9:20 am New Agents in Breast Cancer
Peter Ravdin, MD, PhD, UT Health Science Center, San Antonio, TX
9:20 am – 9:30 am Questions/Answers
9:30 am – 9:50 am Hematology
Swaminathan Padmanabhan, MD, UT Health Science Center, San Antonio, TX
9:50 am – 10:00 am Questions/Answers
10:00 am – 10:20 am Break
10:20 am – 10:40 am Promising Targets for Cancer Treatment-The Hedgehog Pathway
Glen Weiss, MD, The Translational Genomics Research Institute, Phoenix, AZ
10:40 am – 10:50 am Questions/Answers
10:50 am – 11:10 am New Drugs for Lung Cancer
Alan Sandler, MD, Oregon Health Science University, Portland, OR
11:10 am – 11:20 am Questions/Answers
11:20 am – 11:40 am PARP Inhibitors
Monica Mita, MD, MSC, UT Health Science Center, San Antonio, TX
11:40 am – 11:50 am Questions/Answers
11:50 am – 12:10 pm New Drugs for GI Malignancies
Ramesh Ramanathan, MD, TGen Clinical Research Services, Scottsdale, AZ
12:10 pm – 12:20 pm Questions/Answers
12:20 pm – 2:00 pm Lunch and Meet the Experts Session
2:00 pm – 2:20 pm New Drugs for Renal Cancer
Ronald M. Bukowski, MD, Cleveland Clinic Taussig Cancer Center, Cleveland, OH
2:20 pm – 2:30 pm Questions/Answers
2:30 pm – 2:50 pm New Drugs for Sarcoma
Robert G. Maki, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY
2:50 pm – 3:00 pm Questions/Answers
3:00 pm – 3:10 pm Break
3:10 pm – 4:30 pm Case Discussions
4:30 pm – 5:00 pm Questions/Answers
5:00 pm – 5:30 pm Summary/Wrap-up/Evaluation
5:30 pm Adjournment
The Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio is one of the nation’s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of the elite cancer centers in the country to be named a National Cancer Institute-designated Cancer Center, and is one of the only three in Texas. A world leader in developing new drugs to treat cancer, the CTRC Institute for Drug Development is internationally recognized for conducting one of the largest oncology Phase I clinical drug programs in the world, and participates in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit www.ctrc.net